What AI says about Bluejay Therapeutics

Bluejay Therapeutics develops therapies for liver diseases, aiming to shift the treatment paradigm for viral hepatitis and other serious liver conditions. Its science pipeline, led by infectious disease and liver disease experts, includes Brelovitug (BJT-778) with Phase 2 results in chronic hepatitis D showing high virologic response and ALT normalization. The site features news and corporate information, including a definitive acquisition agreement with Mirum Pharmaceuticals, underscoring its role in the rare liver disease space.